E. Dimitra Bednar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
E. Dimitra Bednar has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Mohannad Abu-Hilal
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Canada
5 shared publications - Darshana Seeburruth
Temerty Faculty of Medicine, University of Toronto, ON, Canada
4 shared publications - Edgar Akuffo-Addo
Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada
3 shared publications - Philip Doiron
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
3 shared publications - Ahmed Bagit
Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada
2 shared publications Fares Alkhayal
Division of Dermatology, McMaster University, Hamilton, Canada
2 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1774
Epidemiology of Imported Cutaneous Leishmaniasis: A Narrative Review
Cutaneous leishmaniasis (CL) is a neglected tropical disease (NTD) traditionally associated with rural poverty in endemic regions but is increasingly encountered among international travelers, migrants, and displaced populations. Climate change, globalization, and mass human mobility have altered the epidemiology of CL, expanding the geographic range of competent vectors and increasing the burden of imported disease in non-endemic countries. Imported cases are of particular public health importance because they may serve as sentinels for autochthonous transmission in regions where vectors and reservoir hosts are present. This narrative review synthesizes surveillance data and epidemiological evidence on imported cutaneous and mucocutaneous leishmaniasis (MCL), with particular emphasis on findings from regional and global surveillance networks. We describe demographic, clinical, and travel-related patterns of imported disease, highlight differences between Old World and New World CL, and discuss implications for surveillance, clinical management, and future research in the context of climate change and global migration.
- 12 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1774
Open AccessEpidemiology of Imported Cutaneous Leishmaniasis: A Narrative Review
Cutaneous leishmaniasis (CL) is a neglected tropical disease (NTD) traditionally associated with rural poverty in endemic regions but is increasingly encountered among international travelers, migrants, and displaced populations. Climate change, globalization, and mass human mobility have altered the epidemiology of CL, expanding the geographic range of competent vectors and increasing the burden of imported disease in non-endemic countries. Imported cases are of particular public health importance because they may serve as sentinels for autochthonous transmission in regions where vectors and reservoir hosts are present. This narrative review synthesizes surveillance data and epidemiological evidence on imported cutaneous and mucocutaneous leishmaniasis (MCL), with particular emphasis on findings from regional and global surveillance networks. We describe demographic, clinical, and travel-related patterns of imported disease, highlight differences between Old World and New World CL, and discuss implications for surveillance, clinical management, and future research in the context of climate change and global migration.
- 7 December 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5)
Characteristics, Management, and Outcomes of Rare Topical 5-Fluorouracil-Induced Cutaneous Eruptions: A Systematic Review
- 7 December 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5)
Characteristics, Management, and Outcomes of Rare Topical 5-Fluorouracil-Induced Cutaneous Eruptions: A Systematic Review
- 29 November 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5)
Characteristics, Management, and Outcomes of Rare Imiquimod-Induced Cutaneous Eruptions: A Systematic Review
- 29 November 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5)
Characteristics, Management, and Outcomes of Rare Imiquimod-Induced Cutaneous Eruptions: A Systematic Review
- 4 November 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5) , 554-556
Perceived Gaps in Equity, Diversity, and Inclusion Efforts of Canadian Dermatology Residency Programs: A National Survey of Medical Student Perspectives
- 4 November 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5) , 554-556
Perceived Gaps in Equity, Diversity, and Inclusion Efforts of Canadian Dermatology Residency Programs: A National Survey of Medical Student Perspectives
- 20 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-9
Efficacy and safety of dupilumab in chronic hand eczema: a systematic review
Chronic hand eczema (CHE) significantly impacts patients’ quality of life and remains challenging to manage, especially in topical steroid-refractory cases. Dupilumab, a monoclonal antibody that targets the interleukin-4 receptor alpha, has demonstrated efficacy in moderate-to-severe atopic dermatitis and various other type 2 inflammatory conditions. This systematic review evaluates the effectiveness and safety of dupilumab in the treatment of CHE. A comprehensive search was performed of the Ovid MEDLINE and Embase databases from their inception until March 2024, identifying 20 studies, including randomized controlled trials (RCTs), retrospective and prospective studies, and case reports, involving 366 participants aged 12 years and older with CHE treated with dupilumab. Effectiveness was assessed using the Hand Eczema Severity Index (HECSI), Physician Global Assessment (PGA), and Dermatology Quality of Life Index (DQLI), while safety was evaluated through reported adverse events (AE). Dupilumab consistently improved CHE symptoms, with 40.3% of RCT participants achieving Hand and Foot Investigator’s Global Assessment 0/1 by week 16, and 90% achieving HECSI-75 among treated groups. Improvements were observed across various CHE subtypes, including atopic, irritant contact, and allergic contact dermatitis. Dupilumab was generally well-tolerated, with a 1.64% discontinuation rate due to minor AE, such as conjunctivitis. While herpes was reported in RCTs, no AE were reported in case studies. Dupilumab appears to be a promising treatment option for CHE, offering significant efficacy and a favorable safety profile. However, further research is needed to explore its long-term effectiveness, optimal dosing strategies, and cost-effectiveness.
- 20 February 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-9
Efficacy and safety of dupilumab in chronic hand eczema: a systematic review
Chronic hand eczema (CHE) significantly impacts patients’ quality of life and remains challenging to manage, especially in topical steroid-refractory cases. Dupilumab, a monoclonal antibody that targets the interleukin-4 receptor alpha, has demonstrated efficacy in moderate-to-severe atopic dermatitis and various other type 2 inflammatory conditions. This systematic review evaluates the effectiveness and safety of dupilumab in the treatment of CHE. A comprehensive search was performed of the Ovid MEDLINE and Embase databases from their inception until March 2024, identifying 20 studies, including randomized controlled trials (RCTs), retrospective and prospective studies, and case reports, involving 366 participants aged 12 years and older with CHE treated with dupilumab. Effectiveness was assessed using the Hand Eczema Severity Index (HECSI), Physician Global Assessment (PGA), and Dermatology Quality of Life Index (DQLI), while safety was evaluated through reported adverse events (AE). Dupilumab consistently improved CHE symptoms, with 40.3% of RCT participants achieving Hand and Foot Investigator’s Global Assessment 0/1 by week 16, and 90% achieving HECSI-75 among treated groups. Improvements were observed across various CHE subtypes, including atopic, irritant contact, and allergic contact dermatitis. Dupilumab was generally well-tolerated, with a 1.64% discontinuation rate due to minor AE, such as conjunctivitis. While herpes was reported in RCTs, no AE were reported in case studies. Dupilumab appears to be a promising treatment option for CHE, offering significant efficacy and a favorable safety profile. However, further research is needed to explore its long-term effectiveness, optimal dosing strategies, and cost-effectiveness.
- 7 February 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 29 (4) , 415-416
Equity, Diversity, and Inclusion on Canadian Dermatology Residency Program Websites and Social Media
- 7 February 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 29 (4) , 415-416
Equity, Diversity, and Inclusion on Canadian Dermatology Residency Program Websites and Social Media
- Open Access
- 27 January 2025
- Published by Wiley in Contact Dermatitis
- Vol. 92 (5) , 401-402
If Left to Your Own Devices, Consider Colophony
- 27 January 2025
- Published by Wiley in Contact Dermatitis
- Vol. 92 (5) , 401-402
Open AccessIf Left to Your Own Devices, Consider Colophony
- Open Access
- 26 November 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 29 (2) , 124-130
Characteristics of Patients With Adult-Onset Dermatomyositis at 2 Tertiary Care Centres in Ontario, Canada
Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by progressive muscle weakness and distinctive cutaneous findings. The exact incidence and prevalence of DM in the general population is largely unknown, and data on demographic and clinical features in patients in Canada are lacking. This study aimed to comprehensively evaluate the patients with DM in Southwestern Ontario, Canada. A retrospective chart review was conducted for patients with adult-onset DM at 2 tertiary care centres in Ontario, Canada, over a 13 year period. One hundred fourteen patients were included. The mean age was 59, and 80% of patients were female. Skin and muscle involvement coincided in 63% of patients, while skin predated muscle involvement in 11%. Most common characteristic skin manifestations included Gottron’s papules (69%), Heliotrope sign (66%), V sign (61%), and Shawl sign (56%). Among the 114 patients, 88 (77%) were myopathic while 26/114 (23%) were clinically amyopathic dermatomyositis. In the myopathic type, upper extremity weakness, lower extremity weakness, and dysphagia were present in 87%, 81%, and 29% of patients, respectively. Elevated creatine kinase, C-reactive protein, lactate dehydrogenase, and erythrocyte sedimentation rate were found in 66%, 35%, 33%, and 32%, respectively. Lung disease was reported in 39%, particularly interstitial lung disease. Other associated features included malignancy, cardiovascular disease, and less commonly gastrointestinal disease. DM is a multifaceted autoimmune disease with distinct cutaneous and muscular findings. Our study results align with the growing body of evidence supporting DM as a complex systemic disease with the potential involvement of other organs such as the pulmonary, cardiovascular, and gastrointestinal systems.
- 26 November 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 29 (2) , 124-130
Open AccessCharacteristics of Patients With Adult-Onset Dermatomyositis at 2 Tertiary Care Centres in Ontario, Canada
Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by progressive muscle weakness and distinctive cutaneous findings. The exact incidence and prevalence of DM in the general population is largely unknown, and data on demographic and clinical features in patients in Canada are lacking. This study aimed to comprehensively evaluate the patients with DM in Southwestern Ontario, Canada. A retrospective chart review was conducted for patients with adult-onset DM at 2 tertiary care centres in Ontario, Canada, over a 13 year period. One hundred fourteen patients were included. The mean age was 59, and 80% of patients were female. Skin and muscle involvement coincided in 63% of patients, while skin predated muscle involvement in 11%. Most common characteristic skin manifestations included Gottron’s papules (69%), Heliotrope sign (66%), V sign (61%), and Shawl sign (56%). Among the 114 patients, 88 (77%) were myopathic while 26/114 (23%) were clinically amyopathic dermatomyositis. In the myopathic type, upper extremity weakness, lower extremity weakness, and dysphagia were present in 87%, 81%, and 29% of patients, respectively. Elevated creatine kinase, C-reactive protein, lactate dehydrogenase, and erythrocyte sedimentation rate were found in 66%, 35%, 33%, and 32%, respectively. Lung disease was reported in 39%, particularly interstitial lung disease. Other associated features included malignancy, cardiovascular disease, and less commonly gastrointestinal disease. DM is a multifaceted autoimmune disease with distinct cutaneous and muscular findings. Our study results align with the growing body of evidence supporting DM as a complex systemic disease with the potential involvement of other organs such as the pulmonary, cardiovascular, and gastrointestinal systems.
- Open Access
Pediatric Patients with Osteomyelitis and/or Septic Joint Undergoing Surgical Debridement Have Equivalent Short-Term Outcomes with or without Preoperative MRI
The purpose of this study was to determine if short-term outcomes differed for pediatric patients with suspected musculoskeletal infection with or without a preoperative MRI. This was a multicenter, retrospective review of patients aged 0–16 years who presented with atraumatic extremity pain, underwent irrigation and debridement (I&D), and received at least one preoperative or postoperative MRI over a 10-year period. Primary outcomes were time to OR, total I&Ds, readmission rate, time from OR to discharge, and total number of MRIs. Secondary outcomes entailed the rate at which concurrent osteomyelitis was identified in patients with septic arthritis and the extent of the resulting surgical debridement. Of the 104 patients, 72.1% had a preoperative MRI. Patients with a preoperative MRI were significantly less likely to have surgery on the day of admission. No difference was found between groups regarding total I&Ds, readmission rate, time from OR to discharge, and total number of MRIs. Of the 57 patients diagnosed with septic arthritis, those with a preoperative MRI were significantly more likely to have concurrent osteomyelitis identified and to undergo bony debridement in addition to arthrotomy of the joint. In conclusion, patient outcomes are not adversely affected by obtaining a preoperative MRI despite the delay in time to OR. Although preoperative MRI can be beneficial in ruling out other pathologies and identifying the extent of concurrent osteomyelitis, the decision to obtain a preoperative MRI and timing of surgery should be left to the discretion of the treating surgeon.
Open AccessPediatric Patients with Osteomyelitis and/or Septic Joint Undergoing Surgical Debridement Have Equivalent Short-Term Outcomes with or without Preoperative MRI
The purpose of this study was to determine if short-term outcomes differed for pediatric patients with suspected musculoskeletal infection with or without a preoperative MRI. This was a multicenter, retrospective review of patients aged 0–16 years who presented with atraumatic extremity pain, underwent irrigation and debridement (I&D), and received at least one preoperative or postoperative MRI over a 10-year period. Primary outcomes were time to OR, total I&Ds, readmission rate, time from OR to discharge, and total number of MRIs. Secondary outcomes entailed the rate at which concurrent osteomyelitis was identified in patients with septic arthritis and the extent of the resulting surgical debridement. Of the 104 patients, 72.1% had a preoperative MRI. Patients with a preoperative MRI were significantly less likely to have surgery on the day of admission. No difference was found between groups regarding total I&Ds, readmission rate, time from OR to discharge, and total number of MRIs. Of the 57 patients diagnosed with septic arthritis, those with a preoperative MRI were significantly more likely to have concurrent osteomyelitis identified and to undergo bony debridement in addition to arthrotomy of the joint. In conclusion, patient outcomes are not adversely affected by obtaining a preoperative MRI despite the delay in time to OR. Although preoperative MRI can be beneficial in ruling out other pathologies and identifying the extent of concurrent osteomyelitis, the decision to obtain a preoperative MRI and timing of surgery should be left to the discretion of the treating surgeon.
- 12 September 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (1) , E122-E124
Risk factors for malignancy in adult‐onset dermatomyositis
- 12 September 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (1) , E122-E124
Risk factors for malignancy in adult‐onset dermatomyositis